Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Mephenesin is a centrally acting skeletal muscle relaxant used for the symptomatic treatment of painful muscle spasm in some musculoskeletal diseases (Parkinson's, multiple sclerosis, cerebral palsy). Oral or topical cutaneous administration in several daily doses.
Since the last update we have not found published data on its excretion in breastmilk.
The few known pharmacokinetic data do not allow to predict its possible extraction in breast milk.
The potential side effects are serious (sedation, vomiting and respiratory arrest) and there is a risk of abuse and dependency. (Fanton 2007, Prescrire 2013)
The literature on this drug is scarce, and it is sold in few countries.
Can be used topically but avoid applying it on the breast.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.